South Korea's HK inno.N Targets Cell Therapy, Vaccine Expansion Following $500m IPO

South Korean pharma HK inno.N’s $500m IPO has drawn strong interest with subscriptions from institutional investors marking a record high. The IPO should help it speed up development of cell and gene therapies and beef up its vaccines business.